To our valued Nocdurna patients and providers:

Please be advised that as of October 19, 2023, Antares Pharma, Inc. (a wholly owned subsidiary of Halozyme Therapeutics, Inc.) is no longer marketing Nocdurna, due to the termination of its license agreement with Ferring Pharmaceuticals, the manufacturer of Nocdurna. Nocdurna will remain available at local pharmacies until stock inventory is exhausted.

If you have any questions regarding Nocdurna, please contact Ferring using the contact information below:

  • For adverse event reporting: 1-888-FERRING, Select Option 1
  • For product complaints and all other product-related inquiries: 1-888-FERRING, Select Option 2
  • For medical information inquiries: 1-888-FERRING, Select Option 1

We thank you for your interest in Nocdurna and your understanding during this transition period.